SCHEDULE: Kiniksa Pharmaceuticals: Baker Bros. Waives Conversion Rights

Baker Bros. Advisors LP and affiliated entities have waived their right to convert certain shares into Class A ordinary shares of Kiniksa Pharmaceuticals International, plc, to maintain beneficial ownership below 49.9%.

Summary

• Baker Bros. Advisors LP and its affiliates (collectively, the "Reporting Persons") have filed an amendment to their Schedule 13D regarding their holdings in Kiniksa Pharmaceuticals International, plc.
• On May 21, 2026, the Reporting Persons entered into a Deed of Waiver, agreeing not to convert their Class A1 and Class B1 ordinary shares into Class A or Class B ordinary shares if such conversion would result in them beneficially owning more than 49.9% of the Issuer's outstanding voting rights.
• This waiver is intended to prevent circumvention of the beneficial ownership limitations.
• The Reporting Persons hold a combined total of 3,231,181 Class A ordinary shares, representing 6.9% of the class, for Baker Bros. Advisors LP and Baker Bros. Advisors (GP) LLC.
• Julian C. Baker and Felix J. Baker each beneficially own 3,253,341 Class A ordinary shares, representing 7.0% of the class.
• FBB3 LLC directly holds 7,320 Class A ordinary shares, representing 0.02% of the class.
• The total beneficial ownership, considering potential conversions without the waiver, could reach 32,107,763 Class A ordinary shares, approximately 42.5% of the outstanding shares.
• The Reporting Persons hold these securities for investment purposes and may adjust their holdings based on various factors.
• The filing also details various stock options and restricted stock units held by individuals associated with the Reporting Persons for their service on Kiniksa's Board of Directors.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative update regarding ownership and conversion rights, with no new financial performance data or significant strategic shifts disclosed.

Positives

• Baker Bros. Advisors LP and its affiliates maintain a significant investment in Kiniksa Pharmaceuticals, holding a substantial percentage of Class A ordinary shares.
• The waiver ensures compliance with beneficial ownership limits, potentially preventing regulatory issues or market disruption.
• The Reporting Persons' continued investment suggests confidence in Kiniksa's long-term prospects.
• Several individuals associated with the Reporting Persons hold board positions, indicating active engagement and oversight.

Negatives

• The waiver restricts the ability of Baker Bros. Advisors LP and its affiliates to increase their voting power beyond 49.9%, limiting their potential control.
• The Class A1 and Class B1 ordinary shares are currently not convertible due to beneficial ownership limitations, restricting flexibility.
• The complex structure of beneficial ownership, including options and RSUs, can create opacity for external observers.

Risks

• The beneficial ownership limitation of 49.9% could prevent the Reporting Persons from taking full control or influencing strategic decisions beyond this threshold.
• Changes in the number of outstanding Class A ordinary shares could impact the effective conversion limits for Class A1 and Class B1 shares.
• The Reporting Persons' intention to potentially purchase additional securities or dispose of existing ones introduces market volatility risk.
• The Deed of Waiver imposes restrictions on transferring Class A1 and Class B1 ordinary shares to affiliates without similar adherence to the waiver terms.

Future Outlook

The Reporting Persons may purchase additional securities or dispose of securities in varying amounts and at varying times depending on their assessment of factors including the availability of shares, the Issuer's business prospects, economic and market conditions, and the actions of the Issuer's Board and management. They may also suggest financing strategies and consider acquiring additional securities or disposing of existing ones.

Management Comments

• The Adviser GP is the sole general partner of the Adviser.
• Pursuant to management agreements, the Funds' respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.
• The Adviser has complete and unlimited discretion and authority with respect to the Funds' investments and voting power over investments.
• The policy of the Funds and the Adviser does not permit managing members of the Adviser GP or full-time employees of the Adviser to receive compensation for serving as directors of the Issuer, and the Funds are instead entitled to the pecuniary interest in any compensation received for their service.
• Felix J. Baker, Dr. Biggar and M. Cantey Boyd have no voting or dispositive power and no pecuniary interest in the Share Options or any other securities received as compensation for their Board service.

Industry Context

StockSavvy.ai notes that this filing reflects a common strategy among large institutional investors to manage their ownership stakes and voting power in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors where ownership concentration can be high and regulatory thresholds are critical.

Corporate Governance

Related Party Transactions

• The filing details compensation arrangements for individuals serving on Kiniksa's Board of Directors who are also associated with Baker Bros. Advisors LP, including stock options and restricted stock units. The policy is that the Funds are entitled to the pecuniary interest in any compensation received for their service, not the individuals themselves.

Stakeholder Impact

• Shareholders: The waiver impacts the potential voting power of a significant shareholder group, which could influence future corporate actions and control dynamics.
• Management and Board of Directors: The waiver and ongoing investment strategy of Baker Bros. Advisors LP may influence strategic discussions and decisions.
• Affiliates of Reporting Persons: Restrictions on transferring Class A1 and Class B1 ordinary shares to affiliates without adherence to the Deed of Waiver could impact intra-group transactions.

Next Steps

• The Reporting Persons may purchase additional securities or dispose of securities in varying amounts and at varying times.
• The Reporting Persons may discuss items of mutual interest with the Issuer's management, other Board members, and other investors.
• The Reporting Persons may change their present intentions regarding their holdings based on various factors.
• The Reporting Persons may assess whether to make suggestions to the management of the Issuer regarding financing.
• The Reporting Persons may consider acquiring additional securities of the Issuer.
• The Reporting Persons may consider disposing of some or all of the securities of the Issuer under their control.

Key Dates

Keywords

Schedule 13D, Kiniksa Pharmaceuticals, Baker Bros. Advisors LP, Beneficial Ownership, Class A Ordinary Shares, Deed of Waiver, Share Conversion, SEC Filing, Investment Management